Fuse Science, Inc. announced partnership with Macular Health, LLC, advances in the development of an AREDS2 Drop formulation to combat Age-Related Macular Degeneration. AMD is a medical condition which usually affects older adults and results in a loss of vision because of damage to the retina. In 2001, researchers with the Age-Related Eye Disease Study reported that an AREDS formulation reduced the risk of developing advanced age-related macular degeneration by 25% over a five year period of time.

In 2006, the same research group began a study called AREDS2 to determine if they could improve the formulation. In AREDS2, subjects took one of four formulations daily for a five year period of time. The AREDS2 study results provided new information on preventing vision loss and determined which ingredients are vital to minimizing potential adverse events.

While there is no cure for AMD, Macular Health, by implementing Fuse Science's Drop delivery technology in its formulation, believes that it can help AMD sufferers slow the progression of vision loss, which is the leading cause of blindness in adults in the United States.